Biotech M&A: How Biotech Gets Acquired

Introduction

For most successful biotech companies, acquisition by a larger pharma company is the primary exit path. The economics are straightforward: Big Pharma needs pipeline replenishment to offset patent cliff losses, and biotech companies have the pipeline assets but often lack the commercial infrastructure and financial resources to fully exploit them. This buyer-seller dynamic drives the highest-premium M&A in healthcare and generates significant advisory revenue for healthcare investment banks. Understanding how biotech gets acquired, from the strategic motivations of buyers to the mechanics of the deal process, is essential knowledge for any healthcare banker.

The pharma-biotech M&A dynamic is driven by three forces:

Patent cliff urgency. With $300-400 billion in LOE exposure through 2030, Big Pharma faces a structural revenue gap that internal R&D cannot fill. The largest pharma companies face individual patent cliffs of $20-50 billion in revenue (Merck with Keytruda, AbbVie post-Humira, Pfizer post-COVID, J&J with Stelara). Acquiring late-stage biotech assets is the fastest way to replenish the pipeline because external assets can be in-market generating revenue within 1-3 years, compared to 8-12 years for a new internal discovery program.

R&D productivity gap. Large pharma companies spend $10-20 billion per year on internal R&D but have historically lower R&D productivity than smaller, more focused biotech companies. The bureaucratic overhead, risk-averse culture, and portfolio diversification of large organizations tend to slow decision-making and dilute focus. External acquisition has become the dominant sourcing strategy, with 60-70% of drugs ultimately approved by Big Pharma originating externally (in-licensed or acquired from biotech or academic institutions).

Commercial leverage. Big Pharma can extract more value from a drug than a biotech company because of its global commercial infrastructure: established relationships with thousands of physicians, payer contracting capabilities built over decades, global regulatory expertise across 100+ countries, and manufacturing scale. An oncology drug that a biotech might commercialize for $1.5 billion in peak US sales could reach $3-4 billion globally under a Big Pharma owner with a 5,000-person sales force, established oncologist relationships, and distribution networks in 80+ countries.

Biotech acquisition premiums vary by development stage, therapeutic area, and competitive dynamics:

Reverse Termination Fee

A fee paid by the acquirer to the target if the acquirer fails to close the deal (typically because of financing failure or regulatory block). In biotech M&A, reverse termination fees typically range from 3-8% of deal value and are particularly important in transactions requiring FTC clearance. The reverse termination fee compensates the target for the opportunity cost of having been off the market during the deal period (during which other potential acquirers are deterred) and for the operational disruption and employee attrition that often occurs during a prolonged M&A process. Biotech boards and their advisors negotiate for the highest possible reverse termination fees because a failed deal can be devastating: the stock typically declines to below its pre-deal price, employees leave, and the company's strategic credibility is damaged.

Biotech acquisitions follow one of two process types:

Unsolicited/bilateral approach. The pharma company approaches the biotech directly, often after a positive clinical readout or at a conference meeting. The biotech board evaluates the offer, may run a limited market check (contacting other potential acquirers to verify the offer is fair), and negotiates terms. This process is faster (4-8 weeks from initial approach to signed definitive agreement) but may leave value on the table because of limited competitive tension. However, bilateral deals can also reflect strong relationships between the two management teams and may include favorable non-price terms (employee retention, R&D commitment, location preservation) that a competitive auction would not produce.

Formal sale process. The biotech's board and healthcare banking advisors run a structured sale process, contacting multiple potential acquirers (typically 5-15 pharma and large biotech companies), receiving initial indications of interest, allowing due diligence access to serious bidders, and soliciting binding offers in a compressed timeline. This process takes longer (8-16 weeks) but typically produces higher valuations through competitive bidding. The most effective sale processes create genuine urgency by setting firm deadlines for each stage and maintaining a credible "plan B" (the biotech can remain independent and self-commercialize if bids are inadequate).

The next article covers biotech partnering and licensing, which provides an alternative to full acquisition for monetizing pipeline value.